Financial Performance - SOPHiA GENETICS reported Q2 2025 revenue of $18.3 million, reflecting a 16% year-over-year growth [7][12] - Adjusted gross margin improved to 74.4%, up 120 basis points from the previous year [3][12] - The company experienced a net loss of $22.4 million, which is a 48% increase year-over-year [7][12] Business Highlights - The company signed 35 new core genomics customers in Q2 2025, a significant increase from 19 new customers in Q2 2024 [3][8] - A major multi-year AI breast cancer partnership was established with AstraZeneca, marking the largest contract in the company's history [3][12] - The total number of core genomics customers reached 490 as of June 30, 2025, up from 457 at the end of Q2 2024 [8] Operational Efficiency - Cash burn improved by 35% year-over-year, totaling $8.7 million for the quarter [3][7] - The company performed 95,000 analyses on SOPHiA DDMTM, representing a 9% year-over-year volume growth [8] - The partnership with Dasa, the largest medical diagnostics company in Latin America, was expanded to include additional applications [8] Future Outlook - SOPHiA GENETICS reaffirmed its full-year revenue guidance of $72 million to $76 million, indicating a growth of approximately 10% to 17% compared to FY 2024 [12] - The company expects to approach adjusted EBITDA breakeven by the end of 2026 and achieve positive adjusted EBITDA in the second half of 2027 [12]